Merck & Co., Inc. filings document the regulatory record of a New Jersey pharmaceutical issuer with common stock and multiple debt securities registered on the New York Stock Exchange. The company's disclosures cover operating and financial results, clinical and regulatory matters, material agreements, governance matters and capital-structure changes.
Merck's SEC record includes Form 8-K material-event reports, definitive proxy materials and debt-financing disclosures. Recent filings describe underwritten public offerings of notes, registered securities, shareholder voting matters, board and executive-governance information, and other events tied to the company's pharmaceutical, vaccine and animal health businesses.
Merck & Co., Inc. executive Richard R. DeLuca, Jr. reported a sale of company stock. On 02/06/2026, he sold 37,685 shares of Merck common stock at a weighted average price of $120.9241 per share, in multiple trades between $120.7350 and $121.3054.
After this transaction, DeLuca directly beneficially owned 160,173.834 Merck shares. The filing lists him as Executive Vice President and President, Merck Animal Health, and shows no derivative securities activity for this date.
Merck & Co., Inc. Chairman, CEO and President Robert M. Davis reported two open-market sales of Merck common stock on February 4, 2026. He sold 14,972 shares at a weighted average price of $117.3796 per share and 32,462 shares at a weighted average price of $118.3513 per share, with both transactions coded as sales. After these trades, he directly beneficially owned 443,601.757 shares of Merck common stock.
A holder of Common Stock of the issuer has filed a notice of proposed sale of 20,000 shares under Rule 144. The shares have an indicated aggregate market value of $2,437,676.00 and are planned to be sold on the NYSE around 02/05/2026 through Morgan Stanley Smith Barney LLC Executive Financial Services.
The shares to be sold were acquired from the issuer as restricted stock vesting under a registered plan in several transactions during 2024, including lots of 19,489, 132, 127, and 125 shares. The notice states there are 2,482,022,536 shares of this class outstanding.
An MRK shareholder has filed a notice of intent to sell 6,400 shares of common stock, with an aggregate market value of $765,920, through Morgan Stanley Smith Barney LLC on 02/04/2026 on the NYSE.
The shares to be sold were acquired mainly through restricted stock vesting under a registered plan on several dates in 2024 and through the exercise of 4,000 options on 02/04/2026. The issuer had 2,482,022,536 shares outstanding at the time referenced.
Merck & Co. has a holder filing a notice to sell 47,434 shares of its common stock under Rule 144. The planned sale, through Morgan Stanley Smith Barney LLC, has an aggregate market value of $5,598,136.96 and is expected around 02/04/2026 on the NYSE.
The shares come from restricted stock that vested under a registered plan on 01/26/2026, in the same 47,434‑share amount. The filing also notes that 2,482,022,536 shares of Merck common stock are outstanding.
A holder of MRK common stock filed a notice of proposed resale under Rule 144. The filing covers 15087 shares of common stock with an aggregate market value of 1791824.15, to be sold through Morgan Stanley Smith Barney LLC on the NYSE around 02/04/2026.
These shares were acquired on 02/04/2026 by exercising stock options under a registered plan, with the 15087 shares paid for in cash. The filing notes that 2482022536 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
A holder of MRK common stock has filed a notice of proposed sale under Rule 144 for 41,997 shares. The shares have an aggregate market value of $5,023,311.57, and the planned sale date is February 4, 2026 on the NYSE.
The planned transaction would be executed through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares were acquired on February 4, 2026 by exercising options under a registered plan, with the purchase price paid in cash on the same date.
Merck & Co., Inc. filed a Form 8-K to furnish information about its earnings for the fourth quarter and full year 2025. The filing references a February 3, 2026 press release attached as Exhibit 99.1 and additional supplemental information attached as Exhibit 99.2.
The company states this earnings information is being furnished under Item 2.02, not filed for liability purposes under the Exchange Act, and will only be incorporated into other filings if specifically referenced.
Merck & Co., Inc. executive Jennifer Zachary, EVP and General Counsel, reported an acquisition of 11,583 shares of common stock on January 26, 2026. The shares were distributed as net after-tax stock upon satisfying performance criteria for performance share units granted on March 31, 2023, which paid out at 94 percent of target and included dividends accrued over a three-year performance period ending December 31, 2025.
Following this transaction, Zachary directly holds 68,915.671 shares of Merck common stock.
Merck & Co., Inc. executive vice president and Chief Information & Digital Officer David Michael Williams received 6,112 shares of common stock on January 26, 2026 as an acquired award. These shares were distributed as net after‑tax stock upon meeting performance criteria for performance share units granted on March 31, 2023.
The performance shares were paid out at 94 percent of target awards and included dividends accrued over the three-year performance period ending December 31, 2025. Following this transaction, Williams beneficially owns 30,837.743 shares of Merck common stock, held directly and including shares acquired through dividend reinvestment.